Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment

Fondation Ophtalmologique Adolphe de Rothschild37 enrolled

Overview

Polypoidal choroidal vasculopathy (PCV) is a disease of the choroidal vasculature, that is often regarded as a sub-type of age-related macular degeneration (AMD). However, PCV response to anti-vascular agents differs from the response of typical AMD. This study aims at describing the evolution of the best corrected visual acuity (BCVA) in PCV patients, 28 weeks after they receive one injection of intravitreal aflibercept (2mg).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Polypoidal Choroidal Vasculopathy

Interventions

Intravitreal afliberceptDRUG

Patient receive one intravitreal injection of 2mg aflibercept (as currently recommended in the treatment of AMD)

Eligibility

Sex: ALLMin age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Active polypoidal choroidal vasculopathy, * Visual acuity superior to 1/10 (20/200) and inferior to 6,25/10 (20/32) * Age above 45 * No prior intravitreal treatment, or no response to prior treatment by 3 injections of ranibizumab, or disease recurrence after more than 3 months of stability * Intravitreal injection of aflibercept is indicated by current clinical recommendations Exclusion Criteria: * Simultaneous treatment with another anti-VEGM agent * Diabetic retinopathy * Personal history of vitrectomy or uveitis * Personal history laser photocoagulation and/or verteporphin phototherapy * Tear in the pigmentary epithelium * Chorioretinitis scar * Macular atrophy in the pigmentary epithelium * Treatment with corticosteroids * Eye surgery less than 3 months before inclusion

Locations (3)

CHU Lyon Croix Rousse

Lyon, France

Fondation Ophtalmologique A. de Rothschild

Paris, France

Centre Médical de la Rétine Maison Rouge

Strasbourg, France

Outcomes

Primary Outcomes

Evolution of the best corrected visual acuity (BCVA) measured on the EDTRS scale, between pre-injection and 28 weeks after injection

Time frame: 28 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.